Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo

[1]  A. Burchell,et al.  Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  M. Lal,et al.  Development of a Vaginal Fast-Dissolving Insert Combining Griffithsin and Carrageenan for Potential Use Against Sexually Transmitted Infections. , 2018, Journal of pharmaceutical sciences.

[3]  K. Looker,et al.  Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis , 2017, The Lancet. Infectious diseases.

[4]  B. Herold,et al.  Repeated administration of high‐dose depot medroxyprogesterone acetate does not alter SHIVSF162p3 viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings , 2017, Journal of medical primatology.

[5]  A. Gettie,et al.  An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques , 2017, Drug Delivery and Translational Research.

[6]  L. Rohan,et al.  On-demand microbicide products: design matters , 2017, Drug Delivery and Translational Research.

[7]  H. Chu,et al.  A Comparison of the Natural History of HPV Infection and Cervical Abnormalities among HIV-Positive and HIV-Negative Women in Senegal, Africa , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[8]  C. Litterst,et al.  MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa , 2017, Journal of acquired immune deficiency syndromes.

[9]  K. Palmer,et al.  Pharmacokinetics of the Antiviral Lectin Griffithsin Administered by Different Routes Indicates Multiple Potential Uses , 2016, Viruses.

[10]  M. Einstein,et al.  In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel. , 2016, Gynecologic oncology.

[11]  A. Gettie,et al.  PolyICLC Exerts Pro- and Anti-HIV Effects on the DC-T Cell Milieu In Vitro and In Vivo , 2016, PloS one.

[12]  Ashley J. Mayo,et al.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. , 2016, The New England journal of medicine.

[13]  L. Meyn,et al.  The Effects of Hormones and Vaginal Microflora on the Glycome of the Female Genital Tract: Cervical-Vaginal Fluid , 2016, PloS one.

[14]  A. Gettie,et al.  A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α4β7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3 , 2016, PLoS pathogens.

[15]  Mtn -Aspire Study Team.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women , 2016 .

[16]  K. Looker,et al.  Multipurpose prevention technologies for sexual and reproductive health: mapping global needs for introduction of new preventive products. , 2016, Contraception.

[17]  S. Zaki,et al.  Analysis of putative mucosal SHIV susceptibility factors during repeated DMPA treatments in pigtail macaques , 2015, Journal of medical primatology.

[18]  E. Martinelli,et al.  Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus , 2015, Antimicrobial Agents and Chemotherapy.

[19]  C. Deal,et al.  Multipurpose prevention technologies: the future of HIV and STI protection. , 2015, Trends in microbiology.

[20]  J. Balzarini,et al.  Several N-Glycans on the HIV Envelope Glycoprotein gp120 Preferentially Locate Near Disulphide Bridges and Are Required for Efficient Infectivity and Virus Transmission , 2015, PloS one.

[21]  L. Meyn,et al.  Impact of Bacterial Vaginosis, as Assessed by Nugent Criteria and Hormonal Status on Glycosidases and Lectin Binding in Cervicovaginal Lavage Samples , 2015, PloS one.

[22]  A. Gettie,et al.  MIV-150/Zinc Acetate Gel Inhibits Cell-Associated Simian-Human Immunodeficiency Virus Reverse Transcriptase Infection in a Macaque Vaginal Explant Model , 2015, Antimicrobial Agents and Chemotherapy.

[23]  James Y. Dai,et al.  Tenofovir-based preexposure prophylaxis for HIV infection among African women. , 2015, The New England journal of medicine.

[24]  A. Gettie,et al.  Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides. , 2014, AIDS research and human retroviruses.

[25]  B. Herold,et al.  In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. , 2014, Antiviral research.

[26]  A. Gettie,et al.  A Potent Combination Microbicide that Targets SHIV-RT, HSV-2 and HPV , 2014, PloS one.

[27]  A. Gettie,et al.  MIV-150-Containing Intravaginal Rings Protect Macaque Vaginal Explants against SHIV-RT Infection , 2014, Antimicrobial Agents and Chemotherapy.

[28]  L. Morris,et al.  Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. , 2013, Virology.

[29]  Matthew S. Lewis,et al.  Immune clearance of highly pathogenic SIV infection , 2013, Nature.

[30]  M. Stefanidou,et al.  Griffithsin Protects Mice from Genital Herpes by Preventing Cell-to-Cell Spread , 2013, Journal of Virology.

[31]  R. Hayes,et al.  Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis , 2012, AIDS.

[32]  N. Richardson-Harman,et al.  Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study. , 2012, AIDS research and human retroviruses.

[33]  A. Gettie,et al.  An Intravaginal Ring That Releases the NNRTI MIV-150 Reduces SHIV Transmission in Macaques , 2012, Science Translational Medicine.

[34]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[35]  L. Morris,et al.  The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells. , 2012, Virology.

[36]  Diarmaid J. Murphy,et al.  Sustained Release of the CCR5 Inhibitors CMPD167 and Maraviroc from Vaginal Rings in Rhesus Macaques , 2012, Antimicrobial Agents and Chemotherapy.

[37]  G. Doncel,et al.  Non-specific microbicide product development: then and now. , 2012, Current HIV research.

[38]  J. Peters,et al.  Zinc Acetate/Carrageenan Gels Exhibit Potent Activity In Vivo against High-Dose Herpes Simplex Virus 2 Vaginal and Rectal Challenge , 2011, Antimicrobial Agents and Chemotherapy.

[39]  David Katz,et al.  Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. , 2011, AIDS research and human retroviruses.

[40]  N. Matoba,et al.  Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate , 2011, PloS one.

[41]  Brigitte E. Sanders-Beer,et al.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus , 2011, Mucosal Immunology.

[42]  L. Morris,et al.  Binding of the Mannose-Specific Lectin, Griffithsin, to HIV-1 gp120 Exposes the CD4-Binding Site , 2011, Journal of Virology.

[43]  D. Lowy,et al.  Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. , 2011, Journal of the National Cancer Institute.

[44]  K. Agnew,et al.  Estimating Volume of Cervicovaginal Secretions in Cervicovaginal Lavage Fluid Collected for Measurement of Genital HIV-1 RNA Levels in Women , 2010, Journal of Clinical Microbiology.

[45]  Phalguni Gupta,et al.  Multisite Comparison of Anti-Human Immunodeficiency Virus Microbicide Activity in Explant Assays Using a Novel Endpoint Analysis , 2009, Journal of Clinical Microbiology.

[46]  David C. Montefiori,et al.  Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component , 2009, Proceedings of the National Academy of Sciences.

[47]  S. Pambuccian,et al.  Glycerol monolaurate prevents mucosal SIV transmission , 2009, Nature.

[48]  A. Ouedraogo,et al.  Herpes simplex virus and HIV-1: deciphering viral synergy. , 2008, The Lancet. Infectious diseases.

[49]  S. Kalichman,et al.  Human Immunodeficiency Virus Viral Load in Blood Plasma and Semen: Review and Implications of Empirical Findings , 2008, Sexually transmitted diseases.

[50]  J. Balzarini,et al.  Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent. , 2008, The international journal of biochemistry & cell biology.

[51]  Christopher D Pilcher,et al.  Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection , 2007, AIDS.

[52]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[53]  D. Lowy,et al.  Carrageenan Is a Potent Inhibitor of Papillomavirus Infection , 2006, PLoS pathogens.

[54]  Barry R O'Keefe,et al.  Isolation and Characterization of Griffithsin, a Novel HIV-inactivating Protein, from the Red Alga Griffithsia sp.* , 2005, Journal of Biological Chemistry.

[55]  K. Gustafson,et al.  Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. , 2004, AIDS research and human retroviruses.

[56]  P. Sen,et al.  Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model , 2001, AIDS.

[57]  M. Clementi,et al.  Analysis of HIV‐1 load in blood, semen and saliva: evidence for different viral compartments in a cross‐sectional and longitudinal study , 1996, AIDS.

[58]  D. Ho,et al.  Progesterone implants enhance SIV vaginal transmission and early virus load , 1996, Nature Medicine.